Family Forum / Parenting / Children's Health / September 2007

http://ilenarose.blogspot.com
Health Lover

http://ilena-rosenthal.blogspot.com/2007/08/politics-pr-of-cervical-cancer-while.html

Note from Ilena Rosenthal:  In my recent travels, I have become even
more aware of the enormous push in many countries now for mass
innoculation of our innocent children ...

Much like the Vaccination Industsry Newsgroup Spokespeople here, even
educated medical personnel are being told (and are passing on) only
the Merck propaganda.

When Merck funded 'Women in Government,' a chain of other 'non
profits' were set up to pretend to be unbiased health advocates. Their
#1 job was to sell the' magical thinking' of Merck of the benefits ...
and do a scare job on the masses of people ... much like Myrl Jeffcoat
broadcasts here.

I am feeling that those of us who urge caution and a time to have ALL
the evidence coming out now examined are having our voices drowned out
on usenet and blogs etc. ... so I was happy to see this bit of fresh
air.

Advertising pays. Please read this blog entry on how Merck spent
millions to do what the Gardasil pushers here claim to do for free.

http://ilena-rosenthal.blogspot.com/2007/08/politics-pr-of-cervical-cancer-while.html

http://www.healthcarerepublic.com/news/GP/LatestNews/736017/Schoolgirl-HPV-jabs-
premature/

Schoolgirl HPV jabs 'premature'
05-Sep-07

Introducing a HPV vaccination programme for secondary school girls
would be 'premature', Canadian researchers have warned.
They argue that questions surrounding the efficacy of the HPV vaccine
need to be answered before an immunisation programme can start.

Instead, they suggest that more should be done to educate the public
about the realities of cervical cancer and to promote good nutrition,
smoking cessation and healthy sexual practice.

The DoH has accepted in principle the advice of the Joint Committee on
Vaccination and Immunisation's HPV subgroup that the vaccine be
introduced routinely for schoolgirls in the UK in September 2008,
subject to independent peer review of the cost-benefit analysis.

But the researchers say that a reduction in cases of cervical cancer
would require a vaccine directed against more than the two high-risk
strains of HPV (16 and 18) that Gardasil offers protection against.

Gardasil is the only HPV vaccine available on the market and offers
protection against two thirds of cervical cancer cases.

Previous research from the US has raised doubts over the use of
Gardasil suggesting that it cannot be used to treat those who already
have the infection because it fails to eliminate it.

Writing in the Canadian Medi­cal Association Journal, Dr Abby Lippman
and colleagues, from McGill University in Montreal, said: ‘Information
about the efficacy of Gardasil remains uncertain. To date, only a
handful of randomised controlled trials of sufficient qualify to
quantify for systemic review have been reported.'

Relatively few girls, 1,200 aged 9-15, were enrolled in the clinical
trials of Gardasil, they said.

'Clearly, this is a thin information base on which to construct a
policy of mass vaccination for all girls aged 9-13.'